Unlocking Relief: How to Manage Peripheral Neuropathy in Eosinophilic Granulomatosis with Polyangiitis
"A comprehensive look at the treatment and management of nerve damage associated with EGPA, offering hope and strategies for those affected."
Eosinophilic Granulomatosis with Polyangiitis (EGPA), also known as Churg-Strauss Syndrome, is a rare autoimmune disorder characterized by inflammation of small blood vessels. This inflammation can affect various organs, including the nerves, leading to a condition called peripheral neuropathy. Understanding the link between EGPA and peripheral neuropathy is crucial for effective management and improved quality of life.
Peripheral neuropathy occurs when the nerves outside the brain and spinal cord are damaged. In EGPA, this damage is caused by the inflammation and restricted blood flow resulting from the vasculitis. Symptoms can vary widely, from pain and numbness to muscle weakness, making daily activities challenging.
A recent study published in the Journal of Clinical Neurology sheds light on the clinical characteristics and treatment responses of peripheral neuropathy in EGPA patients. Conducted at a single tertiary center, the study offers valuable insights into managing this challenging condition.
EGPA Overview and Neuropathy Burden
Eosinophilic granulomatosis with polyangiitis (EGPA) is a systemic vasculitis of unknown etiology that occurs in adults with asthma and eosinophilia. Treatment consists mainly of glucocorticoids except in cases with poor prognostic factors indicated by a five-factor score (FFS). However, neuropathy and other organ manifestations often show a poor response to standard glucocorticoid therapy, representing a significant management challenge. Real-world data on patient profiles and disease burden in private practice settings remain limited, underscoring the need for improved understanding of EGPA's impact.
Current Guideline-Based Management
The first Evidence-Based Guideline dedicated specifically to the diagnosis and management of EGPA was published in 2023, presenting 16 statements and five recommendations. EGPA is a rare small-vessel vasculitis occurring in patients with asthma and eosinophilia, and clinical diagnosis remains challenging because no single biomarker is definitive. Expert reviews emphasize that EGPA is a heterogeneous immune-mediated disorder where eosinophilic inflammation, vasculitis, and airway disease coexist in highly variable combinations. European guidelines recommend considering EGPA diagnosis in patients with asthma, chronic rhinosinusitis, and eosinophilia who develop end-organ involvement.
Disease History and Discovery
EGPA, formerly known as Churg-Strauss syndrome, is a rare disease characterized by eosinophil-rich granulomatous inflammation and necrotizing vasculitis predominantly affecting small-to-medium-sized vessels. It was first described in 1951 by Churg and Strauss in asthmatic patients who presented with necrotizing vasculitis, eosinophilic infiltration, and granulomas in the extravascular space. The condition is categorized as a primary systemic vasculitis and usually manifests in three clinical stages. It occurs in people with adult-onset asthma, allergic rhinitis, nasal polyposis, or a combination of these features.
Key Findings from the Study
The study, conducted at Samsung Medical Center, followed 61 patients with EGPA, 46 of whom had peripheral neuropathy. The research aimed to understand the long-term outcomes of these patients, particularly their response to treatment with corticosteroids, with or without intravenous cyclophosphamide.
- High Prevalence: Peripheral neuropathy was present in 75% of EGPA patients.
- Effective Treatment: Combination therapy with corticosteroids and cyclophosphamide significantly improved neurological function.
- Low Relapse Rate: The long-term relapse rate of peripheral neuropathy was very low with the described treatment approach.
- Functional Improvement: Most patients experienced a notable improvement in their modified Rankin Scale (mRS) scores, indicating reduced disability.
Emerging Targeted Therapies
The development of targeted therapeutics has transformed the management of EGPA. A multicenter, double-blind randomized MANDARA trial proved the efficacy of a new treatment approach, broadening the therapeutic scenario for EGPA management. Expert reviews and recommendations on diagnosis and treatment were published in 2026, addressing the challenge that no single biomarker definitively confirms EGPA in clinical practice. These advances represent substantial progress in treatment options that have been made in recent years.
Treatment Challenges and Limitations
EGPA is a necrotizing vasculitis affecting small- and medium-sized blood vessels that causes organ damage due to tissue inflammation and ischemia. While glucocorticoids remain the cornerstone of treatment, neuropathy manifestations often respond poorly to standard therapy. The condition's histopathological characterization by extensive eosinophil infiltration underscores the complexity of managing systemic involvement. These challenges highlight the need for targeted therapies beyond conventional immunosuppression.
Biologic Agents Compared
Benralizumab, a monoclonal antibody against the interleukin-5 receptor, has been compared with mepolizumab in the treatment of EGPA. EGPA is a vasculitis characterized by eosinophilic inflammation, and both agents target the eosinophil pathway through different mechanisms. Various treatments including IL-5-targeting agents and other biologics have recently emerged, prompting regular updates of clinical practice guidelines. Updated treatment approaches for EGPA were published in late 2025 to incorporate these comparative findings.
Taking Control of Your Health
Living with EGPA and peripheral neuropathy can be challenging, but it's important to remember that effective treatments are available. Early diagnosis and aggressive management with corticosteroids and cyclophosphamide can significantly improve neurological function and reduce the risk of relapse. Regular monitoring and close collaboration with your healthcare team are essential to achieving the best possible outcome. Don't hesitate to seek support and information to help you navigate this journey. With the right approach, you can maintain a good quality of life and manage your condition effectively.
Current Practice Patterns Across Centers
Real-world practice patterns of EGPA remain poorly defined across clinical settings. A 2026 study aimed to describe current diagnostic and therapeutic approaches across experienced European centres, identifying areas of convergence and variability. The goal of this research was to inform future standardization of care for EGPA patients. Understanding these practice variations is essential for improving consistent management of the condition.
Advancing Treatment Frontiers
The management of newly diagnosed EGPA continues to evolve with ongoing research into targeted therapeutics. EGPA is a small-vessel vasculitis associated with anti-neutrophil cytoplasmic antibodies, characterized by blood and tissue eosinophilia, severe respiratory manifestations, and multiorgan involvement. The EGPA treatment market is growing, with North America dominating at a CAGR of 5.1% in 2023, attributed to increasing asthma prevalence and environmental changes. Future advances in healthcare are expected to further boost market growth and treatment options.
EGPA Within the Vasculitis Spectrum
EGPA is a rare, multi-system, inflammatory disease belonging to the group of anti-neutrophil cytoplasmic antibody (ANCA)-associated vasculitides. Previously known as Churg-Strauss syndrome, it is characterised by late-onset asthma, eosinophilia, and vasculitis affecting small-to-medium vessels. The condition's rarity and multi-organ involvement create systemic challenges in diagnosis and long-term management. Recognition of EGPA within the broader AAV spectrum is important for differential diagnosis and treatment planning.
Patient Journey and Quality of Life
An enhanced understanding of EGPA in clinical practice may help identify areas where patient management could be improved. Studies examining real-world demographics, patient diagnostic journey, disease burden, treatment patterns, and health-related quality of life (HRQoL) provide valuable insights into the patient experience. The patient profile and treatment pattern for EGPA in real-world settings remain poorly understood because of the condition's rarity and lack of recognition. Characterizing demographics, clinical characteristics, and symptoms through retrospective chart reviews helps bridge this knowledge gap.